Payment overview · 2025
General Payments
$274.98
14 reported records · 8 companies
Healthcare provider profile · identity verified
Faisal Bukhari, MD SC
Allopathic & Osteopathic Physicians|Internal Medicine · SULLIVAN, IL · NPI 1376545509
Verified facts
What the public records show
CMS Open Payments records show Faisal Bukhari, MD SC received $274.98 in general payments during 2025 across 14 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 417 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $89.91 | 32.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.85 | 17.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.06 | 14.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.98 | 10.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.42 | 8.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.74 | 5.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.58 | 5.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.44 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.98 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $89.91 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.85 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.85 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.06 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 417 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
417 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1285 | 181 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1141 | 193 |
| Furosemide | Furosemide | 830 | 128 |
| Metoprolol Tartrate | Metoprolol Tartrate | 574 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 546 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 94 |
| Lisinopril | Lisinopril | 528 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 510 | 108 |
| Omeprazole | Omeprazole | 498 | 88 |
| Trazodone Hcl | Trazodone Hcl | 478 | 92 |
| Gabapentin | Gabapentin | 470 | 80 |
| Sertraline Hcl | Sertraline Hcl | 460 | 57 |
| Potassium Chloride | Potassium Chloride | 458 | 76 |
| Tramadol Hcl | Tramadol Hcl | 443 | 78 |
| Losartan Potassium | Losartan Potassium | 419 | 71 |
| Eliquis | Apixaban | 417 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 408 | 69 |
| Metformin Hcl | Metformin Hcl | 384 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 367 | 69 |
| Warfarin Sodium | Warfarin Sodium | 352 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 344 | 67 |
| Carvedilol | Carvedilol | 315 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 309 | 63 |
| Famotidine | Famotidine | 303 | 47 |
| Donepezil Hcl | Donepezil Hcl | 295 | 46 |
| Buspirone Hcl | Buspirone Hcl | 294 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 290 | 56 |
| Divalproex Sodium | Divalproex Sodium | 278 | 38 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 261 | 21 |
| Mirtazapine | Mirtazapine | 260 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 258 | 52 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 251 | 42 |
| Risperidone | Risperidone | 251 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 245 | 48 |
| Xarelto | Rivaroxaban | 242 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 50 |
| Allopurinol | Allopurinol | 217 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 212 | 117 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 25 |
| Jardiance | Empagliflozin | 177 | 28 |
| Entresto | Sacubitril/Valsartan | 176 | 16 |
| Pregabalin | Pregabalin | 176 | 35 |
| Alendronate Sodium | Alendronate Sodium | 171 | 33 |
| Levetiracetam | Levetiracetam | 168 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 76 |
| Cephalexin | Cephalexin | 153 | 81 |
| Montelukast Sodium | Montelukast Sodium | 153 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 49 |
| Memantine Hcl | Memantine Hcl | 140 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 140 | 26 |
| Meloxicam | Meloxicam | 138 | 25 |
| Simvastatin | Simvastatin | 130 | 28 |
| Metformin Hcl Er | Metformin Hcl | 123 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 119 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 118 | 23 |
| Nystatin | Nystatin | 115 | 56 |
| Spironolactone | Spironolactone | 109 | 22 |
| Prednisone | Prednisone | 108 | 30 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 107 | 20 |
| Januvia | Sitagliptin Phosphate | 105 | 13 |
| Nifedipine Er | Nifedipine | 105 | 17 |
| Ozempic | Semaglutide | 104 | 14 |
| Olanzapine | Olanzapine | 100 | 22 |
| Ezetimibe | Ezetimibe | 96 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 96 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 18 |
| Myrbetriq | Mirabegron | 94 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 48 |
| Oxybutynin Chloride | Oxybutynin Chloride | 90 | 16 |
| Levofloxacin | Levofloxacin | 89 | 57 |
| Lovastatin | Lovastatin | 89 | 11 |
| Torsemide | Torsemide | 88 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 37 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 35 |
| Lacosamide | Lacosamide | 79 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 79 | 53 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 77 | 23 |
| Memantine Hcl Er | Memantine Hcl | 76 | 11 |
| Lorazepam | Lorazepam | 74 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 13 |
| Scopolamine | Scopolamine | 70 | suppressed |
| Tradjenta | Linagliptin | 69 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 11 |
| Finasteride | Finasteride | 65 | 14 |
| Alprazolam | Alprazolam | 64 | 12 |
| Propranolol Hcl | Propranolol Hcl | 60 | 11 |
| Meclizine Hcl | Meclizine Hcl | 58 | 12 |
| Latanoprost | Latanoprost | 54 | suppressed |
| Sucralfate | Sucralfate | 54 | 13 |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Azithromycin | Azithromycin | 52 | 32 |
| Humulin R | Insulin Regular, Human | 52 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 48 | suppressed |
| Baclofen | Baclofen | 47 | suppressed |
| Fluconazole | Fluconazole | 46 | 30 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 16 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 44 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 44 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 31 |
| Digoxin | Digoxin | 43 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Aripiprazole | Aripiprazole | 41 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Loperamide | Loperamide Hcl | 33 | 19 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Clonidine | Clonidine | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Timolol Maleate | Timolol Maleate | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Novolin R | Insulin Regular, Human | 30 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 29 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Calcium Acetate | Calcium Acetate | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Tobramycin | Tobramycin | 27 | 24 |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Enulose | Lactulose | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 12 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Ceftriaxone | Ceftriaxone Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Admelog | Insulin Lispro | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Phenytoin | Phenytoin | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 14 | 14 |
| Novolog | Insulin Aspart | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274.98 · 14 records | Otsuka America Pharmaceutical, Inc. | BREZTRI, CREON, ELIQUIS, FREESTYLE LIBRE 3, INGREZZA, MOUNJARO, NURTEC ODT, REXULTI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error